APX3330 blocks NF-κB function, which decreases inflammation and reverses the progression from pre-AML to frank AML in mice bearing AML-associated epigenetic mutations often observed in healthy individuals with clonal hematopoiesis (Cai et al, manuscript submitted). Here, NFKB1 is linked to acute myeloid leukemia.